Barbara L. Asselin, M.D.

Barbara L. Asselin, M.D.

Contact Information

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 667
Rochester, NY 14642

Office: (585) 276-4113
Fax: (585) 276-1128
Administrative: (585) 276-4113

Professional Bio

Barbara Asselin, MD, an attending physician and faculty member at URMC for over 25 years, graduated from Boston College, Boston, MA and then received her medical degree from University of Rochester School of Medicine & Dentistry. After completing her residency in Pediatrics at University of Massachusetts, Worcester, MA, she returned to Rochester and completed fellowship training in Pediatric Hematology/Oncology at the University of Rochester.



As a board-certified pediatrician and pediatric hematologist/oncologist, Dr. Asselin has provided care for pediatric patients with cancer and blood disorders, conducted research trials in pediatric malignancies, served as Principal Investigator to the Children's Oncology Group and Dana-Farber Leukemia Consortium, and authored numerous research studies, articles and book chapters related to her clinical and research interests. Since 2009, she has worked as an academic hospitalist in the division of Pediatric Hospital Medicine providing comprehensive inpatient medical care for children with acute and chronic illnesses. Dr. Asselin's academic interests include clinical research to improve the care of patients with pediatric cancers, medical education for medical students and residents, and development of individualized patient care plans for patients with complex, multispecialty needs.

Research Bio

Dr. Asselin's research expertise is in clinical trials and clinical research to improve the care of patients with pediatric cancers. She serves as study investigator for two major international cooperative research groups, the Children's Oncology Group and the Dana-Farber Leukemia Consortium.



Through these groups she is actively involved in design and development of a number of studies of the treatment and biology of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Her specific areas of expertise are L-asparaginase pharmacology and immunology in treatment of ALL, treatment of T-cell disease (ALL and NHL), and the role of cardioprotection in prevention of cardiotoxocity in long-term survivors.

Awards & Honors (Local)

Best Doctors in America 2004 - Present
Alpha Omega Alpha (AOA) Medical Honor Society 2003 - Present
George Washington Goler Associate Professor of Pediatrics 2002 - 2005
Jacob Gitelman Award | Cancer Action and Gilda's Club of Rochester 2002
Society of Pediatric Research 1998 - Present
Research Fellow, Leukemia Society of America 1987 - 1990
Wilmot Cancer Research Fellow | James P. Wilmot Foundation 1987 - 1990
Bradford Fellow | Department of Pediatrics | University of Rochester Medical Center 1985 - 1986
Rochester Academy of Medicine OB-GYN Annual Award 1980
Paul Gyorgy Annual Award, La Leche League International 1980
Honor Society of Phi Beta Kappa 1977
Honor Society of the Order of the Cross and Crown 1977

Recent Journal Articles

Showing the 5 most recent journal articles. 52 available »

2015
Asselin BL, Rizzari C. "Asparaginase pharmacokinetics and implications of therapeutic drug monitoring.doi: 10.3109/10428194.2014.1003056 [Epub ahead of print]." Leuk Lymphoma. 2015; : 1-26.
2014
Tower RL, Jones TL, Camitta BM, Asselin BL, Bell BA, Chauvenet A, Devidas M, Halperin EC, Pullen J, Shuster JJ, Winick N, and Kurtzberg J. "Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: A report from the Children's Oncology Group." Journal of Pediatric Hematology/Oncology. 2014; 36(5): 353-61.
2014
Salzer WL, Asselin BL, Plourde PV, Corn T, and Hunger SP. "Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia." Acad Sci. 2014; 1329(2014): 81-92.
2014
Bleyer A, Asselin BL, Koontz SE, and Hunger SP. "Clinical application of asparaginase activity levels following treatment with pegaspargase.doi: 10.1002/pbc.25299. [Epub ahead of print]". Pediatr Blood Cancer. 2014; .
2014
Asselin BL, Fisher V. "Impact of clinical and subclinical hypersensitivity to asparaginase in acute lymphoblastic leukemia. [Epub ahead of print] doi: 10.1188/14.CJON". Clin J Oncol Nurs. 2014; 18(6): E102-12.

Current Appointments

Professor - Department of Pediatrics, Pediatric Hospitalist (SMD) - Primary
Professor - Cancer Center

Specialties

Pediatrics - American Board of Pediatrics
Pediatric Hematology-Oncology - American Board of Pediatrics

Education

MD | Medicine | University of Rochester School of Medicine and Dentistry1981
BS | Arts and Sciences | Boston College1977

Post-Doctoral Training & Residency

Fellowship in Pediatric Hematology/Oncology, H. Cohen, MD, Ph.D at University of Rochester Medical Center07/01/1984 - 06/30/1987
Residency in Pediatrics at University of Massachusetts Medical School06/01/1982 - 07/01/1984
Internship in Pediatrics at University of Massachusetts Medical School06/23/1981 - 05/31/1982